The company buys Belgium’s EsoBiotec for $425m.
ApexOnco Front Page
Recent articles
The acquisition of Araris follows a 2023 discovery collaboration.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Conferences ramp up, and ASH abstracts near.
The group goes after a KRAS-related target on which Boehringer recently gave up.